Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 2

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---

     79,474  
     72,069 
  
    Warrant expense 
     -  
     (7,323,685) 
     -  
     (7,323,685)
  
    Changes in fair value of warrant liability 
     (267,274) 
     3,341,829  
     203,400  
     3,341,829 
  
    Gain or Loss on settlement of warrant exercise 
     -  
     3,071,252  
     -  
     3,071,252 
  
    Total other income (expenses) 
     (225,256) 
     (845,076) 
     282,874  
     (838,535)

    Loss from operations before income taxes 
     (1,595,959) 
     (2,354,090) 
     (3,858,201) 
     (7,358,943)

    Provision for income taxes 
     -  
     -  
     -  
     - 

    Net Loss 
    $(1,595,959) 
    $(2,354,090) 
    $(3,858,201) 
    $(7,358,943)

    Net loss per share – basic and diluted 
    $(2.10) 
    $(9.54) 
    $(5.68) 
    $(82.14)

    Weighted average common shares – basic and diluted 
     761,218  
     246,816  
     679,210  
     89,592 

The accompanying notes are an integral part of
these financial statements.

2

ENDRA Life Sciences Inc.

Condensed Consolidated Statements of Stockholders’
Equity

(Unaudited)

Nine Months Ended September 30,2024

    Series A Convertible  
    Series B Convertible  

    Additional  

    Total 

    Preferred Stock  
    Preferred Stock  
    Common stock  
    Paid in  
    Stock  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Payable  
    Deficit  
    Equity 
  
    Balance as of December 31